IMVT
Immunovant, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +18.2% ·
share flow +11.3% ·
net new positions +15.4%
— formula
Broad accumulation — rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 92 | +8 | 58.13M | $2.24B | +14 | −5 |
| Q1 2026 | 86 | +8 | 53.00M | $1.32B | +12 | −4 |
| Q4 2025 | 78 | -2 | 55.44M | $1.41B | — | −2 |
| Q3 2025 | 16 | 0 | 40.91M | $659.48M | +1 | −2 |
| Q2 2025 | 14 | -2 | 41.55M | $664.87M | — | −2 |
| Q1 2025 | 13 | +2 | 9.17M | $156.74M | +2 | — |
| Q4 2024 | 11 | -2 | 8.24M | $204.11M | — | −2 |
| Q3 2024 | 12 | +1 | 7.03M | $200.30M | +1 | — |
| Q2 2024 | 11 | — | 7.29M | $192.47M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (passive) | 3.09M | +14.4% | $52.76M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 1.67M | +10.4% | $28.59M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 1.67M | +10.4% | $28.59M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 4 | Viking Global Investors ✦ | 1.11M | -20.8% | $19.05M | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 5 | Point72 Asset Management ✦ | 801.93K | New | $13.70M | 0.0% | New | 1 | SEC ↗ |
| 6 | T. Rowe Price ✦ | 744.54K | -18.7% | $12.72M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 7 | T. Rowe Price ✦ | 744.54K | -18.7% | $12.72M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 8 | Norges Bank ✦ (passive) | 637.95K | 0.0% | $10.90M | 0.0% | Held | 4 | SEC ↗ |
| 9 | Renaissance Technologies ✦ | 395.90K | +389.4% | $6.77M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 10 | Citadel Advisors ✦ | 327.82K | -26.2% | $5.60M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 11 | Millennium Management ✦ | 153.24K | +4.2% | $2.62M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 12 | Marshall Wace ✦ | 138.48K | New | $2.37M | 0.0% | New | 1 | SEC ↗ |
| 13 | Marshall Wace ✦ | 138.48K | New | $2.37M | 0.0% | New | 1 | SEC ↗ |
| 14 | D. E. Shaw & Co. ✦ | 50.53K | -25.3% | $863,626 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 15 | D. E. Shaw & Co. ✦ | 50.53K | -25.3% | $863,626 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 16 | Wellington Management ✦ | 25.03K | -4.7% | $427,763 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 17 | Wellington Management ✦ | 25.03K | -4.7% | $427,763 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 18 | Wellington Management ✦ | 25.03K | -4.7% | $427,763 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 19 | Wellington Management ✦ | 25.03K | -4.7% | $427,763 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 20 | Adage Capital Partners ✦ | 21.20K | -92.9% | $362,308 | 0.0% | ▼ Trim | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Point72 Asset Management | $13.70M | 0.0% |
| Marshall Wace | $2.37M | 0.0% |
| Marshall Wace | $2.37M | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 215 holders, 110.50M shares, $2.64B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 3.06K sh · $134,953
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology